<DOC>
	<DOCNO>NCT01486771</DOCNO>
	<brief_summary>Intravitreal injection pegaptanib induce regression Proliferative Diabetic Retinopathy ( PDR ) reduce need retinal photocoagulation .</brief_summary>
	<brief_title>Macugen Proliferative Diabetic Retinopathy Study With Extended Dosing ( M-PDRS ED )</brief_title>
	<detailed_description>Primary Objective : To establish efficacy intravitreal pegaptanib injection regression retinal neovascularization secondary high-risk PDR , compare standard panretinal photocoagulation ( PRP ) Secondary Objective : To maintain regression PDR induction phase intravitreal pegaptanib injection administer 12-week interval , compare standard PRP To maintain regression PDR induction phase retinal photocoagulation apply area ischemia ( Selective Laser Photocoagulation ) , compare standard PRP To evaluate rate recurrence neovascularization 6 intravitreal pegaptanib injection To determine intravitreal pegaptanib reduce area and/or volume concomitant diabetic macular edema , assessed leakage fluorescein angiography ( FA ) and/or optical coherence tomography ( OCT ) To determine intravitreal pegaptanib injection maintain reduce loss best-corrected visual acuity</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>1 . Eligible eye active PDR high risk characteristic ( HRC ) define DRS . All eye must meet least one follow criterion : Mild neovascularization disc ( NVD ) least 1/4 1/3 disc area show standard photograph 10A DRS . Moderate neovascularization retina elsewhere ( NVE ) least 1/2 disc area show standard photograph 7 DRS . 2 . ETDRS visual acuity score great equal 24 letter ( approximately 20/320 ) less equal 85 letter ( approximately 20/20 ) ETDRS visual acuity protocol screen visit . 3 . Eyes mild preretinal hemorrhage ( PRH ) mild vitreous hemorrhage ( VH ) interfere clear visualization macula optic disc eligible study . 4 . Evaluating physician believe PRP safely withhold 3 week . 1 . Presence moderate dense PRH VH prevents clear visualization macula and/or optic disc . 2 . Presence either : significant epiretinal membrane involve macula , OR proliferative diabetic membrane along major retinal arcade extensive enough cause either : significant vitreomacular traction , OR significant impairment visual acuity . 3 . Presence tractional retinal detachment . 4 . Severe ischemia involve foveal avascular zone determine fluorescein angiography perform initial screen visit . 5 . Significant medium opacity ( due cornea , anterior chamber , lens ) preclude clear visualization macula optic disc . 6 . Presence neovascular glaucoma without hyphema . 7 . Previous treatment intravitreal steroid injection study eye within 6 month baseline . 8 . Previous treatment peribulbar steroid injection study eye within 90 day baseline 9 . Previous PRP laser treatment study eye within 90 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
</DOC>